MannKind Corporation (MNKD)
Price:
3.28 USD
( + 0.04 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Vertex Pharmaceuticals Incorporated
VALUE SCORE:
8
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Aurinia Pharmaceuticals Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
NEWS
Why MannKind Stock Tumbled on Thursday
fool.com
2026-02-26 18:19:24Investors weren't pleased with the biotech's bottom-line decline. It also missed the consensus analyst estimate for that metric.
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-26 16:57:50MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
zacks.com
2026-02-26 13:30:26While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2026-02-26 13:16:16MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
2026-02-26 08:00:00Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
2026-02-19 09:00:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com
2026-02-18 09:00:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
globenewswire.com
2026-02-09 06:05:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
seekingalpha.com
2026-02-06 03:41:04MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addressable market and supporting MNKD's long-term growth thesis.
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
prnewswire.com
2026-01-29 13:31:00/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
globenewswire.com
2026-01-26 06:05:00MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
MoneyShow's Best Investment Ideas For 2026: Part 5
seekingalpha.com
2026-01-15 12:30:00MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know
zacks.com
2026-01-13 13:01:06MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stuart Tross Sells 47,006 Shares of MannKind (NASDAQ:MNKD) Stock
defenseworld.net
2026-01-11 04:56:44MannKind Corporation (NASDAQ: MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the sale, the insider owned 985,007 shares of the company's stock, valued at $6,235,094.31.
MannKind Provides Business Updates and 2026 Growth Drivers
globenewswire.com
2026-01-08 08:05:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD
defenseworld.net
2026-01-05 04:34:48Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ: MNKD) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,871 shares of the biopharmaceutical company's stock after selling 480,182 shares during the period. Voya Investment Management
No data to display
Why MannKind Stock Tumbled on Thursday
fool.com
2026-02-26 18:19:24Investors weren't pleased with the biotech's bottom-line decline. It also missed the consensus analyst estimate for that metric.
MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-26 16:57:50MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript
Compared to Estimates, MannKind (MNKD) Q4 Earnings: A Look at Key Metrics
zacks.com
2026-02-26 13:30:26While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
MannKind (MNKD) Reports Q4 Loss, Tops Revenue Estimates
zacks.com
2026-02-26 13:16:16MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
2026-02-26 08:00:00Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
2026-02-19 09:00:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
globenewswire.com
2026-02-18 09:00:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
globenewswire.com
2026-02-09 06:05:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion
seekingalpha.com
2026-02-06 03:41:04MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addressable market and supporting MNKD's long-term growth thesis.
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
prnewswire.com
2026-01-29 13:31:00/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
globenewswire.com
2026-01-26 06:05:00MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
MoneyShow's Best Investment Ideas For 2026: Part 5
seekingalpha.com
2026-01-15 12:30:00MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know
zacks.com
2026-01-13 13:01:06MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Stuart Tross Sells 47,006 Shares of MannKind (NASDAQ:MNKD) Stock
defenseworld.net
2026-01-11 04:56:44MannKind Corporation (NASDAQ: MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total value of $297,547.98. Following the sale, the insider owned 985,007 shares of the company's stock, valued at $6,235,094.31.
MannKind Provides Business Updates and 2026 Growth Drivers
globenewswire.com
2026-01-08 08:05:00DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD
defenseworld.net
2026-01-05 04:34:48Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ: MNKD) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,871 shares of the biopharmaceutical company's stock after selling 480,182 shares during the period. Voya Investment Management